Arena Pharmaceuticals clinical trials
Acquired by Pfizer, Mar 11, 2022 · source ↗
The registry lists 17 studies whose lead sponsor is Arena Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 30, 2025.
- 17studies on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Arena Pharmaceuticals became part of Pfizer
- 17
- First submitted after Arena Pharmaceuticals became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Arena Pharmaceuticals’s studies test, most studies first; none is open now — 5 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 17 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 417
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Arena Pharmaceuticals17 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. All Pfizer studies →
- Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)TerminatedNCT04043455Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisCompletedNCT03996369Phase 3
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisCompletedNCT03945188Phase 3
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic DermatitisCompletedNCT04162769Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy VolunteersCompletedNCT00619931Phase 1
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary CholangitisTerminatedNCT03155932Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT02536404Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal PainCompletedNCT03155945Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumTerminatedNCT03072953Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel SyndromeTerminatedNCT04655599Phase 1
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisCompletedNCT02447302Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal ManifestationsTerminatedNCT03139032Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance InsomniaCompletedNCT00664664Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking CessationCompletedNCT02044874Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Single-dose Safety Study of APD916 in Healthy VolunteersCompletedNCT01093508Phase 1
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Single-Dose Safety Study of APD791 in Healthy VolunteersCompletedNCT00529646Phase 1
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer
- Safety and Efficacy Study of APD125 in Patient With InsomniaCompletedNCT00452179Phase 2
Sponsor listed in the registry: Arena Pharmaceuticals · First submitted before Arena Pharmaceuticals became part of Pfizer